168 related articles for article (PubMed ID: 21245103)
21. Combined treatment of Nimotuzumab and rapamycin is effective against temozolomide-resistant human gliomas regardless of the EGFR mutation status.
Chong DQ; Toh XY; Ho IA; Sia KC; Newman JP; Yulyana Y; Ng WH; Lai SH; Ho MM; Dinesh N; Tham CK; Lam PY
BMC Cancer; 2015 Apr; 15():255. PubMed ID: 25886314
[TBL] [Abstract][Full Text] [Related]
22. Function of aberrant EGFR in malignant gliomas.
Sugawa N; Yamamoto K; Ueda S; Morita N; Kita M; Nishino H; Fushiki S; Okabe T
Brain Tumor Pathol; 1998; 15(1):53-7. PubMed ID: 9879464
[TBL] [Abstract][Full Text] [Related]
23. Targeting a unique EGFR epitope with monoclonal antibody 806 activates NF-kappaB and initiates tumour vascular normalization.
Gan HK; Lappas M; Cao DX; Cvrljevdic A; Scott AM; Johns TG
J Cell Mol Med; 2009 Sep; 13(9B):3993-4001. PubMed ID: 19432811
[TBL] [Abstract][Full Text] [Related]
24. Cyclooxygenase-2 is a novel transcriptional target of the nuclear EGFR-STAT3 and EGFRvIII-STAT3 signaling axes.
Lo HW; Cao X; Zhu H; Ali-Osman F
Mol Cancer Res; 2010 Feb; 8(2):232-45. PubMed ID: 20145033
[TBL] [Abstract][Full Text] [Related]
25. Cells with intense EGFR staining and a high nuclear to cytoplasmic ratio are specific for infiltrative glioma: a useful marker in neuropathological practice.
Burel-Vandenbos F; Turchi L; Benchetrit M; Fontas E; Pedeutour Z; Rigau V; Almairac F; Ambrosetti D; Michiels JF; Virolle T
Neuro Oncol; 2013 Oct; 15(10):1278-88. PubMed ID: 23935154
[TBL] [Abstract][Full Text] [Related]
26. Selective Targeting of Glioblastoma with EGFRvIII/EGFR Bitargeted Chimeric Antigen Receptor T Cell.
Jiang H; Gao H; Kong J; Song B; Wang P; Shi B; Wang H; Li Z
Cancer Immunol Res; 2018 Nov; 6(11):1314-1326. PubMed ID: 30201736
[TBL] [Abstract][Full Text] [Related]
27. Boron neutron capture therapy of EGFR or EGFRvIII positive gliomas using either boronated monoclonal antibodies or epidermal growth factor as molecular targeting agents.
Yang W; Barth RF; Wu G; Tjarks W; Binns P; Riley K
Appl Radiat Isot; 2009 Jul; 67(7-8 Suppl):S328-31. PubMed ID: 19467880
[TBL] [Abstract][Full Text] [Related]
28. Comparing implementations of magnetic-resonance-guided fluorescence molecular tomography for diagnostic classification of brain tumors.
Davis SC; Samkoe KS; O'Hara JA; Gibbs-Strauss SL; Paulsen KD; Pogue BW
J Biomed Opt; 2010; 15(5):051602. PubMed ID: 21054076
[TBL] [Abstract][Full Text] [Related]
29. Epidermal growth factor receptor (EGFR)-retargeted measles virus strains effectively target EGFR- or EGFRvIII expressing gliomas.
Paraskevakou G; Allen C; Nakamura T; Zollman P; James CD; Peng KW; Schroeder M; Russell SJ; Galanis E
Mol Ther; 2007 Apr; 15(4):677-86. PubMed ID: 17299404
[TBL] [Abstract][Full Text] [Related]
30. Radiolabeled novel mAb 4G1 for immunoSPECT imaging of EGFRvIII expression in preclinical glioblastoma xenografts.
Liu X; Dong C; Shi J; Ma T; Jin Z; Jia B; Liu Z; Shen L; Wang F
Oncotarget; 2017 Jan; 8(4):6364-6375. PubMed ID: 28031526
[TBL] [Abstract][Full Text] [Related]
31. EGFRvIII stimulates glioma growth and invasion through PKA-dependent serine phosphorylation of Dock180.
Feng H; Hu B; Vuori K; Sarkaria JN; Furnari FB; Cavenee WK; Cheng SY
Oncogene; 2014 May; 33(19):2504-12. PubMed ID: 23728337
[TBL] [Abstract][Full Text] [Related]
32. Adult diffuse gliomas produce mRNA transcripts encoding EGFR isoforms lacking a tyrosine kinase domain.
Guillaudeau A; Durand K; Rabinovitch-Chable H; Pommepuy I; Mesturoux L; Robert S; Chaunavel A; Moreau JJ; Labrousse F
Int J Oncol; 2012 Apr; 40(4):1142-52. PubMed ID: 22159595
[TBL] [Abstract][Full Text] [Related]
33. Mutant EGFR is required for maintenance of glioma growth in vivo, and its ablation leads to escape from receptor dependence.
Mukasa A; Wykosky J; Ligon KL; Chin L; Cavenee WK; Furnari F
Proc Natl Acad Sci U S A; 2010 Feb; 107(6):2616-21. PubMed ID: 20133782
[TBL] [Abstract][Full Text] [Related]
34. Identification of the epitope for the epidermal growth factor receptor-specific monoclonal antibody 806 reveals that it preferentially recognizes an untethered form of the receptor.
Johns TG; Adams TE; Cochran JR; Hall NE; Hoyne PA; Olsen MJ; Kim YS; Rothacker J; Nice EC; Walker F; Ritter G; Jungbluth AA; Old LJ; Ward CW; Burgess AW; Wittrup KD; Scott AM
J Biol Chem; 2004 Jul; 279(29):30375-84. PubMed ID: 15075331
[TBL] [Abstract][Full Text] [Related]
35. Thyroid receptor-interacting protein 13 and EGFR form a feedforward loop promoting glioblastoma growth.
Hu L; Shen D; Liang D; Shi J; Song C; Jiang K; Menglin Ren ; Du S; Cheng W; Ma J; Li S; Bi X; Barr MP; Fang Z; Xu Q; Li W; Piao H; Meng S
Cancer Lett; 2020 Nov; 493():156-166. PubMed ID: 32860853
[TBL] [Abstract][Full Text] [Related]
36. Molecular targeting and treatment of an epidermal growth factor receptor-positive glioma using boronated cetuximab.
Wu G; Yang W; Barth RF; Kawabata S; Swindall M; Bandyopadhyaya AK; Tjarks W; Khorsandi B; Blue TE; Ferketich AK; Yang M; Christoforidis GA; Sferra TJ; Binns PJ; Riley KJ; Ciesielski MJ; Fenstermaker RA
Clin Cancer Res; 2007 Feb; 13(4):1260-8. PubMed ID: 17317838
[TBL] [Abstract][Full Text] [Related]
37. MRI features can predict EGFR expression in lower grade gliomas: A voxel-based radiomic analysis.
Li Y; Liu X; Xu K; Qian Z; Wang K; Fan X; Li S; Wang Y; Jiang T
Eur Radiol; 2018 Jan; 28(1):356-362. PubMed ID: 28755054
[TBL] [Abstract][Full Text] [Related]
38. Growth and metastasis suppression of glioma xenografts expressing exon 4-deletion variant of epidermal growth factor receptor by monoclonal antibody CH12-mediated receptor degradation.
Wang H; Shi B; Zhang Q; Jiang H; Hu S; Kong J; Yao M; Yang S; Li Z
FASEB J; 2012 Jan; 26(1):73-80. PubMed ID: 21917986
[TBL] [Abstract][Full Text] [Related]
39. Growth suppression of intracranial xenografted glioblastomas overexpressing mutant epidermal growth factor receptors by systemic administration of monoclonal antibody (mAb) 806, a novel monoclonal antibody directed to the receptor.
Mishima K; Johns TG; Luwor RB; Scott AM; Stockert E; Jungbluth AA; Ji XD; Suvarna P; Voland JR; Old LJ; Huang HJ; Cavenee WK
Cancer Res; 2001 Jul; 61(14):5349-54. PubMed ID: 11454673
[TBL] [Abstract][Full Text] [Related]
40. Monoclonal antibody 806 inhibits the growth of tumor xenografts expressing either the de2-7 or amplified epidermal growth factor receptor (EGFR) but not wild-type EGFR.
Luwor RB; Johns TG; Murone C; Huang HJ; Cavenee WK; Ritter G; Old LJ; Burgess AW; Scott AM
Cancer Res; 2001 Jul; 61(14):5355-61. PubMed ID: 11454674
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
